Summary Cell death after treatment with chemotherapy is exerted by activation of apoptosis. and the p53 protein has been shown to actively participate in this process. This recent focus on TP53 status as a possible determinant of cancer therapy response has raised the question of whether or not mutations in the TP53 gene have an influence on paclitaxel therapy. The TP53 status has been analysed at the DNA level in tumours from 45 ovanan cancer patients randomized to treatment with paclitaxel and cisplatin or cyclophosphamide and cisplatin. Therapy response was obtained for 38 patients with clinically evaluable disease after initial surgery. The positive response rate to the paclitaxeU cisplatin therapy was 8500 vs 61 0o for the patients who received the cyclophosphamide/cisplatin regimen. A significant difference in relapsefree survival in favour of paclitaxel/cisplatin chemotherapy was found (P = 0.001). A total of 33 tumour samples (73%o) had detectable sequence alterations in the TP53 gene. When relapse-free survival was estimated for all patients with TP53 alterations in their tumours. a significant better outcome for the paclitaxel/cisplatin group was found compared with the patient group receiving cyclophosphamide and cisplatin therapy (P = 0.002). We did not observe an association between TP53 tumour status and prognosis for patients who received paclitaxeUcisplatin combination treatment. indicating that the effect of this therapy is not influenced by this parameter.
Txxo-thirds of patients w ith epithelial ovarian cancer are diagnosed w-ith adx anced stages. Treatment includes surgical resection of the primarx tumour and metastases to reduce tumour xolume. foHlow ed bv cvtotoxic chemotherapy. As manx as 60-73%E of these oxarian carcinomas are responsix-e to drug regimens. includinc the DNAbinding agents cyclophosphamide and cisplatin. or the microtubulistabilizing agent paclitaxel together w-ith cisplatin (IMcGuire et al. 1996) . The effectixeness of cancer chemotherapy is restricted by failure of some tumours to respond and by the appearance of resistant cell populations in patients xho relapse after initial response. Understanding resistance to chemotherapy is dependent on the elucidation of the molecular mechanisms bx w-hich anti-cancer drugs induce cell death (Kerr et al. 1972 : Vaux. 1993 ). It has been show-n in sexeral tx pes of carcinomas that cell death after treatment ,A-ith chemotherapy inxolxves actix ation of apoptosis ( Eastman. 1990 : Hickman. 1992 ). Exposure of the cells to both platinum analogues or taxanes is associated wvith morphological changes in apoptosis lBhalla et al. : Haxrileskx et al. 1995 .
Apoptosis is a geneticallv controlled process. and a xarietx of genes haxe been identified codin2 for inducers or inhibitors of this process. The tumour-suppressor protein p53 has been shown to exert marked effects on apoptosis in some cells in addition to its inxolxvement in the control of the cell cycle and in DNA repair. Multiple studies haxe rexealed that wild-type p53 protein and members of the Bcl-2 protein family-(includinc Bcl-2 and Bax) undergo complex regulatix e interactions during the modulation of programmed cell death. Wild-type p53 has been shoxwn to induce an up-regulation of Bay mRNA (NMixvashita et al. 1994 ) and a concomitant dox%-n-regulation of Bcl-2 mRNA ( Haldar et al. 1994) that correlates to the induction of programmed cell death (Mixashita et al. 1994) . It has been reported that cells functionally deficient in p53 or w-ith elexated lexels of either Bcl-' or BCI-XL are relativelv resistant to cxtotoxic agents. such as platinum analogtues (Lou-e et al. 1993a : Dole et al. 1995 .
Alterations of the TP53 gzene. either as a result of point mutations or deletions. are the most frequent abnormalities described in human cancers. Abnormal p53 protein has been reported to be associated with shorter disease-free survival and poor clinical outcome of oxvarian cancer patients (Lex esque et al. 1995 : X an der Zee et al. 1995 . A significant association has been reported betw een TP53 missense mutations and tumours resistance to cisplatin-based therapy (Righetti et al. 19961 .
During the last X ears. the inclusion of paclitaxel in the treatment of adx anced oxarian cancer has extended the disease-free surnxial period. The fact that more than 50%-' of stage Ill and IV epithelial oxarian cancers are reported to haxe TP53 sequence alterations (Hainaut et al. 1997) . and the recent focus on TP53 status as a possible determinant of cancer therapy response. raised the question of w-hether or not the TP53 gene has an influence on paclitaxel therapy. Sexveral groups haxe used x-arious cell sy stems to inx estigate the topic (Delia et al. 1996 : Hawkins et al. 1996 : Wahl et al. 1996 : Wu and El-Dierx. 1996 . Some authors could demonstrate an increased paclita.xel sensitixvitx for cells harbouring inactix ated p53 protein (Hawkins et al. 1996 : Wahl et al. 1996 . whereas followxed bv S min at 95:C before storingr at -20'C.
The TP53 cDNA was amplified usincg the followxing primers (sense) 5'-GTGACACGCFTCCCTGGATTG-3' and (antisense) 5'-AGTGGGGAACAAGAAGTGGAG-3'. as described prexiously (Frebourg et al. 1992 ). 65^C for 1 min 10 s and 78-C for 2 min. followxed bx 2 min at 78'C using a GeneAmp PCR System 2400 (Perkin Elmer). The PCR products were anal-sed for purity by running 7.5%c PAGE.
followed by staininc xith ethidium bromide. After purification using MicroSpin Columns (Pharmacia Biotech). TP53 cDNAs xere submitted to direct sequencing using four internal primers. coxering the open reading frame. and the Dye Terminator Cycle Sequencing Ready Reaction DNA Sequencing Kit (Perk-in Elmer). The sequence analy-sis wxas performed in an automated 373 DNA Sequencer (Applied Biosy stems). All sequence alterations reported in Table I wxere confirmed by independent PCR reactions.
Mutation analyses of TP53 using genomic DNA Genomic DNA was isolated using standard procedures )phenolchloroform extraction and ethanol precipitation) in cases for wxhich frozen specimens were axailable. Extraction of genomic DNA from paraffin-embedded tissues xxas performed using ten 5-pm sections from each block. The samples xxere deparaffinized using txxo rinses x ith xy lene. followxed by one x-ith absolute ethanol. in a microcentrifuge tube. After the final centrifugation. all ethanol wxas remoxed and the tissue pellet xxas briefly dried (55-C for 30 min. DNA xxas extracted using the Puregene DNA Isolation Kit (Gentra Systems). After dissolxing the final DNA pellet in 100 1l (DNA Hydration Solution). the sample wxas stored at 4'C. PCR primer sequences for analy ses of exons 2. 5-9 and 11 of the TP53 gene using temporal temperature gradient electrophoresis (TTGE) wxere as prexiously described for constant denaturant gel electrophoresis (CDGE) analyses (Borresen et al. 1991 : Smith-Sorensen et al. 1993 ). see Andersen and Borresen 1995 for modification of primers for exon 2 and 7 ( Andersen and Borresen. 1995) . PCR using DNA isolated from paraffin-embedded tissue as template contained 2.5 U of AmpliTaq Gold (Perkin Elmer) in a total x olume of 50 gl. When template DNA x as from frozen tissue extracted with phenol-chloroform. the PCR contained 2.5 U of AmpliTaq DNA Polymerase (Perkin Elmer). The PCR products wxere analysed for purity by running 7.5%/e PAGE followed bx staininc xxith ethidium bromide.
TTGE is a modification of the concept of denaturing gradient gel electrophoresis (DGGE) described by Fischer and Lerman (1983) and x as performed using l10%c polvacrxvlamide gels ( acrx 1-amide bis ratio 37.5:1 ) in 1.25 x TAE buffer (50 mr Tris-acetate. 1.25 m_% EDTA. pH 8.0). The gels contained 31%c denaturant (100c denaturant corresponds to 7 \t urea and 40%')(Xv/X) formamide) for analysing exons 6. 9 and 11 fragments. and 37%-c denaturant for analxsing exons 2. 5. 7 and 8 fragments.
Electrophoresis wxas perfomed in 1.25 x TAE running buffer using the DCode U'nixersal Mutation Detection System (Bio-Rad). The temperature x as programmed to increase from 63-C to 68C Splice site mutations were observed in four cases. and these alterations are expected to lead to altered transcripts. resulting in abnormal proteins. A majority of the described sequence alterations occurred in highly conserved regions encoding motifs important for the p53 protein structure (Vogelstein and Kinzler. 1994) . Two of these regions (codon 163-195 and codon [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] contribute to the binding of a zinc atom. which is important for stabilizing the protein structure. and 12 of the described sequence changes affect the zinc binding regions. The TP53 mutation spectrum of the present study does not diverge from other reports of ovarian carcinomas (Hainaut et al. 1997 ).
TP53 satus in relation to outcome of treatment Out of the 17 patients with complete or partial response to paclitaxel/cisplatin therapy. six relapsed during the observation period.
Four of these tumours harboured TP53 alterations. Among the 11 patients without relapse during the observation time. TP53 mutations in tumours were found in eight cases. In the cyclophosphamide/cisplatin treatment group. relapse occurred in 8 of the 11 cases with complete or partial response. Seven of these tumours had TP53 alterations. In the tumours from the three relapse-free patients. one was found to contain a TP53 mutation.
After cytotoxic therapy. nine patients had progressive disease (two in the paclitaxel/cisplatin group and seven in the cyclophosphamide/cisplatin group). Tumours with TP53 alterations were found in seven of these cases. one in the paclitaxel/cisplatin group and six in the cyclophosphamide/cisplatin group (Table 2) . Pacitaxel and TP53 status 379 Within the group of patients treated with cyclophosphamide and cisplatin. relapse had taken place more often in patients with TP53 tumour alterations (16 out of 17, 94%) compared with patients with wild-type TP53 in their tumours (three out of five. 60%). For the group of patients treated with paclitaxel in combination with cisplatin. relapse had occurred in 7 out of 16 patients (44%) with TP53 mutations in their tumours compared with three out of seven patients (43%) having tumours with wild-type TP53.
When RFS was estimated for patients with TP53 tumour alterations, the paclitaxel/cisplatin group had a significantly better outcome than the cyclophosphamide/cisplatin group (P = 0.002). as shown in Figure 1 . Specific regions in the TP53 gene, encoding domains important for binding the zinc atom, have previously been found to have influence on doxorubicin treatment of breast carcinomas (Aas et al, 1996) . RFS for patients with TP53 alterations affecting the two zinc binding domains L2 and L3 (eight patients in the paclitaxel/cisplatin group and four patients in the cyclophosphamide/cisplatin group) showed a significantly better outcome for the paclitaxel/cisplatin-treated patient group than for the cyclophosphamide/cisplatin-treated group (P = 0.001).
DISCUSSION
Despite the introduction of combined use of cytoreductive surgery and chemotherapy in advanced epithelial ovarian cancer patients. long-term survival has not improved significantly over the last few years. Prognosis is currently based on clinical and histopathological parameters. and identification of new prognostic markers would be of great importance in identifying individuals who may benefit from new and more effective therapy. So far, the gene most frequently reported to be mutated in ovarian cancer is TP53 (Marks et al, 1991; Mazars et al. 1991 : Okamoto et al. 1991 . The high frequency of mutations may indicate an important role for this gene in ovarian carcinogenesis, and TP53 aberrations have been reported to be associated with advanced stages of the disease (Buttitta et al. 1997) . It has also been observed that patients with p53 mutations have a significantly shorter RFS than patients with p53-negative tumours (Levesque et al, 1995; Buttitta et al, 1997) . The treatment in these studies included platinum-based chemotherapy.
In the present study. TP53 alterations were observed in 73% of the tumours. All TP53 missense mutations detected affected codons previously reported to contain sequence alterations in other ovarian cancer studies. The most frequently mutated TP53 codons in ovarian carcinomas are 273, 175 and 248. We detected sequence alterations of codon 273 and 175 in four and three cases, respectively. but none in codon 248. When considering the patients treated with cyclophosphamide and cisplatin. a tendency toward a shorter RFS was observed for patients with TP53 mutations compared with the patients with wild-type TP53 (P = 0.15).
However. with the rather small number of cases studied, this difference was not statistically significant. Whether or not the TP53 status influences the outcome of paclitaxel trament has previously been investigated in different cell systems (Delia et al, 1996 : Hawkins et al. 1996 : Wahl et al. 1996 : Wu and El-Diery. 1996 . Primary embryo fibroblasts from p53-null mice have shown a ninefold increased cytotoxicity to paclitaxel compared with corresponding control cells (Wahl et al. 1996) . Sensitivity to paclitaxel was less increased in fibroblasts isolated from heterozygous TP53 (+/-) mouse embryos compared with TP53 (-4-) mouse embryo cells. A sevenfold increased cytotoxicity to paclitaxel in normal human fibroblasts after targeted degradation of wild-type p53 through expression of HPV E6 has also been reported (Hawkins et al, 1996 : Wahl et al, 1996 . On the other hand. Wu and El-Deiry (1996) (Lavarino et al. 1997 ). In the present study, no association was seen between TP53 tumour status and prognosis within the patient group treated with pacitaxel and cisplatin. while within the group treated with cyclophosphamide and cisplatin there seems to be a better prognosis and less relapse for patients with tumours with wild-type TP53.
In an attempt to answer the central question of whether ovarian cancer patients with TP53 mutations in their tumours benefit from pacitaxel-inclusive chemotherapy, we compared the two different treatment groups in which TPS3 alterations were observed. A significantly better outcome for the group treated with pacditaxel and cisplatin was found. The present study is, however, too small to evaluate whether or not specific TP53 mutations influence treatment response. as recently reported for doxorubicin treatment of breast carcinomas (Aas et al. 1996) .
Several studies have demonstrated that the product of the TP53 tumour-suppressor gene is responsible for the G, checkpoint (Kastan et al, 1991; Kuerbitz et al. 1992 (Clarke et al. 1993 : Lowe et al, 1993b . The main mechanism of cytotoxicity of the anti-cancer drug cisplatin is thought to be through induction of DNA damage, primarily in the form of intrastrand cross-links at the N-7 positions of adjacent guanine bases (Sherman and Lippard. 1987 Recently. it has been suggested that p53 also plays a role in regulating the G,/M transition (Agarwal et al. 1995; Guillouf et al, 1995 : Stewart et al. 1995 . However. it has also been documented that the G,/M transition is regulated independently of p53, as cells that are p53 null or with mutated p53 show DNA damage-induced G, arrest (Kastan et al, 1991; Kuerbitz et al, 1992) . The anti-cancer drug paclitaxel promotes assembly of tubulin dimers to form excessively stable microtubules by preventing depolymerization (Schiff et al. 1979) . Cells incubated with paclitaxel accumulate in the G,/M phase (Horwitz, 1992) . Induction of apoptosis after pacitaxel treatment both in vitro (Bhalla et al, 1993; Gangemi et al. 1995) and in vivo : Milross et al. 1995 has been observed. Our results do not reveal any differences in the outcome of treatment with paclitaxel in combination with cisplatin between patients with wild-type or mutant TP53 in their tumours.
Paclitaxel has been reported to induce both wild-type p53 and Waf-l protein (Blagosklonny et al, 1995) . Induction of Waf-l has also been demonstrated in cells lacking p53 expression and therefore is assumed to be independent of functional p53. Interestingly, Blagosklonny et al (1995) demonstrated that depletion of c-raf-l, an upstream regulator of MAP kinase. significantly abrogated the ability of pacitaxel to induce both wild-type p53 as well as Waf-1. Based on these recent results, we studied Waf-1 protein expression in tumours from patients treated with the pacitaxel combination (data not shown). As for the TP53 status, we could not observe any association between prognosis and Waf-l status, but Waf-l expression was more common in wild-type TP53 tumours than in tumours with TP53 gene alterations.
The results of the study by Haldar et al (1996) have indicated that pacitaxel may execute some of its anti-cancer action through phosphorylation of Bcl-2. Bcl-2 is an intracellular integral membrane protein that resides in the outer mitochondrial membrane, nuclear envelope and parts of the endoplasmic reticulum. It has been observed that Bcl-2 by dimerizing with the bax protein protects cells from the apoptotic effect of bax homodimers (Sato et al, 1994; Ym et al, 1994; Yang et al, 1995) . Experiments have further indicated that phosphorylated Bcl-2 is unable to form heterodimers with bax, leading to more bax homodimers and cell death (Haldar et al. 1996 ). It appears that Bcl-2 phosphorylation is not always a necessary component of the apoptotic response to paclitaxel in all cell types. Pacitaxel-induced apoptosis in some tumour cell lines has been suggested to act through Bcl-2-independent pathways (Bhalla et al, 1994) . Considering these reports, we also included Bcl-2 expression analysis of the tumours from patients treated with paclitaxel in combination with cisplatin (data not shown). We could not observe any association between Bcl-2 status and prognosis, but expression was less common in wild-type TP53 tumours than in tumours harbouring TP53 mutations.
